Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TK2 | O00142 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15187541 | 1.00 | TK1 (0.60) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL11875571 | 1.00 | TK1 (0.60) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5982157 | 1.00 | TK1 (0.60) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL114560 | 1.00 | TK1 (0.60) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL11874785 | 1.00 | TK1 (0.60) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Triphosphate SCHEMBL27782747 | 0.91 | POLB (0.57) | TK1LMNASMN1; SMN2ALBPKM | |
| Uracil SCHEMBL3509076 | 0.89 | TK1 (0.49) | TK1LMNASMN1; SMN2TK2 | |
| SCHEMBL29834198 | 0.88 | TK1 (0.55) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2722555 | 0.88 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL13497202 | 0.88 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6723 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740010-A1 | NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY | Agilent Technologies, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-12577554-B2 | Methods for purification of messenger RNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260028616-A1 | METHODS AND APPARATUS FOR DUPLEX NUCLEOTIDE PURIFICATION | AGILENT TECHNOLOGIES, INC. (US) | 2026-01-29 | — | — | US | claimed |
| EP-4677078-A1 | MANUFACTURE OF MESSENGER RNA WITH KP34 POLYMERASE | Sanofi Pasteur Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025262186-A2 | THERAPEUTIC OLIGONUCLEOTIDES FOR TREATING DISEASES BEING ASSOCIATED WITH OR CAUSED BY A MISSENSE, NONSENSE OR IN-FRAME INDEL MUTATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-12-26 | — | — | WO | claimed |
| WO-2025217472-A1 | IMMUNOREGULATORY ANTIGEN-PRESENTING VESICLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250268994-A1 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | TRANSLATE BIO, INC. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-6355421-B1 | POLYMER COMPRISING NON-POLYNUCLEOTIDE PROBING NUCLEOBASE SEQUENCE COMPLEMENTARY TO TARGET SEQUENCE, FIRST AND SECOND ARM SEGMENTS COVALENTLY LINKED TO, OR EMBEDDED WITHIN, PROBING SEQUENCE, AT LEAST ONE LINKED DONOR AND ONE ACCEPTOR MOIETY | BOSTON PROBES, INC. | 2002-03-12 | — | — | US | claimed |
| US-6326479-B1 | PURINE RICH OLIGOMERS PEPTIDE NUCLEIC ACID (PNA) OLIGOMERS. | BOSTON PROBES, INC. | 2001-12-04 | — | — | US | claimed |
| EP-1072679-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies Inc. (US) | 2001-01-31 | — | — | EP | claimed |
| EP-1064399-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO DETECTION COMPLEXES | Boston Probes, Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1027372-A1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS | Boston Probes, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| EP-1025120-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO PNA MOLECULAR BEACONS | Boston Probes, Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999049293-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO DETECTION COMPLEXES | BOSTON PROBES, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1999022018-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO PNA MOLECULAR BEACONS | BOSTON PROBES, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999021881-A1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS | BOSTON PROBES, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1998027425-A1 | LARGE-SCALE PURIFICATION OF FULL LENGTH OLIGONUCLEOTIDES BY SOLID-LIQUID AFFINITY EXTRACTION | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-25 | — | — | WO | claimed |